ERG is an ETS-family TF that is required for normal hematopoiesis. It is also a potent oncogene associated with both solid organ and hematological malignancies [3] [4] [5] [6] [7] [8] . Although the precise role of ERG during normal hematopoiesis has yet to be fully elucidated, it has been shown that mice with one functional allele have reduced circulating HSCs, while the loss of both, results in embryonic lethality due to impaired proliferation of HSCs that appear to be normally specified in the embryo 3, 8 . The presence of an extra copy of Erg on the other hand has been implicated in the myeloproliferative phenotype of the mouse model of Down's syndrome 9 .
Chromosomal translocations that result in the expression of oncogenic ERG fusion proteins have been identified in leukemia, Ewing's sarcoma and in 40-80% of prostate carcinomas [4] [5] [6] . The EWS-ERG fusion protein is not only able to transform mesenchymal progenitors into sarcomas but also transforms committed lymphocytes into T-cell leukemias in vivo 10 . Notably, ERG over expression in T-ALL was shown to be an independent risk factor for an adverse outcome 11 whereas low expression is associated with a highly favourable outcome. Indeed, high ERG expression correlates with disease relapse and unfavourable characteristics in T-ALL ( Figure   S1 ). Comparable observations have also been made in relation to cytogenetically normal acute
For personal use only. on January 11, 2018 . by guest www.bloodjournal.org From 4 myeloid leukemia and ERG expression. However, the transforming effects of ERG have only recently been demonstrated in lymphoid cells 12 and the precise mechanism of ERG over expression is not known. As ERG over expression does not appear to be due to an increase in DNA content, it may be a consequence of epigenetic, transcriptional or posttranscriptional/translational regulatory mechanism driving increased ERG activity in this patient cohort.
The upstream regulators of ERG have not been systematically analyzed in hematopoietic cells. In a survey of Scl targets that employed high throughput sequencing of chromatin immuno precipitation (ChIP-seq) material from HPC-7 cells (a stem cell factor dependent, multipotential, mouse hematopoietic cell line), a region 85 kb downstream of the mouse promoter, mErg +85, showed strong Scl binding 13 . We have previously shown that this region targets fetal liver blood cells in F 0 mouse transgenics 13 . We now report that transgenic mice expressing ERG under control of the vav promoter die from T-ALL and that ERG plays a non-redundant role that promotes the proliferation of T-ALL cells. We also show that the ERG +85 enhancer targets adult HSCs and thymic T-cell progenitors. This enhancer is active in primary human T-ALL cells and is regulated by the T-ALL oncogenes, SCL, LYL1 and LMO2.
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MATERIALS AND METHODS
Generation of transgenic animals
The vav-ERG3 transgenic lines were generated by sub-cloning a 1.4 Kb fragment of human ERG3 cDNA 7 into the HS21/45-vav vector replacing hCD4 [14] [15] . This construct was microinjected into pronuclei of fertilized C57BL6 F1 oocytes and several founders were identified by PCR. Transgenic ERG expression was verified by RT-PCR and western blot (data not shown). The data presented here is based on analysis of three different founders with no difference in the phenotypes identified. Multiple SV/Erg+85/venus lines were generated by amplifying enhancer sequences from mouse genomic DNA and generating founders by pronuclear injection of fertilized ova with the enhancer reporter fragment. The data shown in this manuscript is from L8373.
Cell lines, Primary Cells, and Xenografts
Molt4, REH and 416B cells were maintained as per DSMZ. OP9-DL1 cells were maintained as described 16 . CD34 + /CD38 -cells from CB were isolated as described 16 . To obtain pro-T and pre-T cells, CD34 + /CD38 -cells were co-cultured with OP9-DL1 cells as described 16 . 
Pro-T (CD34
ChIP Assay
ChIP assays were performed as described 18 . Enrichment was measured by real-time PCR using SYBR green (ChIP-PCR; Invitrogen) or by Agilent custom HD-ChIP arrays (ChIPchip; ArrayExpress/A-MEXP-1853). See supplementary information for details.
ERG expression
RNA isolation (QIAGEN) and cDNA synthesis was performed using standard protocols.
Relative ERG mRNA levels were determined by quantitative SYBR Green (Stratagene) qPCR or semi-quantitative RT-PCR, and normalized against a control gene. ERG protein levels were 7 determined by western blot using an anti-ERG antibody (Santa Cruz, sc-354X) and anti-TOPO 1 control (BD Pharmingen, 556597).
Stable transfection assays
The ERG +85 fragment was PCR amplified from human genomic DNA and sub-cloned into the pGL2-promoter vector (Promega). The plasmid was electroporated into MOLT4, REH and 416B cells with pGKneo and tested in stable transfection assays as described 18 . Mutations were introduced by PCR to replace the element indicated with a XhoI restriction site, and confirmed by sequencing. 
ERG knockdown
TCRβ2 rearrangements and Notch1 mutations
Genomic DNA was purified from the thymus and tail of wild type and ERG transgenic mice and PCR amplified using primers to examine Dβ2-Jβ rearrangements as described 20 .
Germline PCR product was obtained from tail DNA. The heterodimerization (HD) and PEST domains of NOTCH1 were amplified by PCR, sequenced and compared to wild type Notch1 sequence. See supplementary information for details.
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RESULTS
ERG induces T-acute lymphoblastic leukemia in mice
Mice transplanted with syngeneic hematopoietic progenitors over-expressing ERG develop megakaryoblastic leukemia and die within 100 days 19 . To assess whether the spectrum of ERG-induced leukemia may be wider following transgenic expression of ERG in the haematopoietic system throughout ontology, we generated transgenic mice expressing the human ERG3 hematopoietic isoform 21 under the control of the vav promoter using the HS21/45-vav vector [14] [15] showing that mice transplanted with bone marrow cells over-expressing ERG also develop T-ALL in association with Notch1 mutations 12 .
ERG plays a non-redundant role in proliferating human T-ALL cells
ETS domain genes encode a super-family of TFs organized into 11 subfamilies based on domain structures, which are conserved from worm and fly to mammals 26 . Twelve of the 31
ETS genes including erg are expressed in blood/endothelial precursors in zebrafish embryos 27 but despite similarities in structure and expression pattern, Erg plays a non redundant role in blood/endothelial development in both fish and mice 3, 27 . ERG is also required for the proliferation and maintenance of acute megakaryocytic leukaemic cells 7, 19, 28 . To establish whether ERG plays a non redundant role in T-ALL cells, we performed knockdown experiments in MOLT-4 cells using previously characterised anti-ERG and control shRNA vectors 19 .
Knockdown of ERG was evident both by RT-PCR (data not shown) and immunoblot analysis of MOLT4 cells following stable transduction with a retrovirus expressing shRNA that targets ERG ( Figure 2A ). There was no reduction in FLI1 protein with which ERG shares ~ 80% amino acid homology (data not shown). ERG knockdown led to a significant change in cell morphology with; increased cell size and nuclear/cytoplasmic ratio, appearance of multinucleate cells and cells with abnormal nuclei and multiple nucleoli, and increased cytoplasmic vacuolation and blebbing (compare kd ERG with kd Con in Figure 2B ). These changes were accompanied by increased apoptosis and impaired cell cycle progression with prolongation of the S-phase ( Figure   2C ) and a significant reduction in growth potential ( Figure 2D ). Taken together with data showing impaired proliferation of ERG deficient Jurkat T-ALL cells 12 , these results show that endogenous ERG expression in T-ALL cells plays a non-redundant role in supporting leukemic cell proliferation.
The ERG stem cell enhancer is active in human T-cell progenitors and in human T-ALL
The transcriptional control of ERG expression during normal T-lymphopoiesis and in T-ALL is poorly understood. To gain insights into the regulation of ERG in these cells, we used by early thymocytes is associated with T-cell commitment (reviewed in 29 ). We used this culture system to harvest pro-T and pre-T cell populations to assess ERG expression and chromatin accessibility at the ERG locus.
ERG expression in pro-T cells was considerably lower than in undifferentiated CB CD34 + cells but higher than in pre-T cells in which expression was barely detectable by RT-PCR ( Figure 3A ). ERG expression in the MOLT4 T-ALL cell line and in primary T-ALL cells harvested from NOD/SCID xenografts (five pro-T-ALLs and one pre-T-ALL), was considerably higher than in normal pro-and pre-T cells and comparable to the expression levels in CD34 + cells ( Figure 3A ). To assess chromatin accessibility at the ERG locus, we performed chromatin immuno precipitation (ChIP) assays for acetylated lysine residues 9 and 14 on histone H3
(H3K9/14Ac). XALL-29 which shows the lowest level of acetylation at the proximal promoter and enhancer also shows the lowest level of ERG mRNA and protein expression ( Figure 3A and Figure S2 ). The human ERG gene has at least two recognized promoters separated by ~ 165kb.
The distal promoter (DP) has previously been reported to be inactive in T-ALL with promoter CpG methylation 30 . Consistent with this and other data, active chromatin marks are present on the proximal promoter (PP) and depleted at the DP in CD34 + stem/ progenitors, pro-and pre-T cells and MOLT4 leukaemic cells ( Figure 3B ). Significantly, chromatin accessibility at the ERG enhancer diminishes during the pro-T to pre-T transition but is significantly elevated in MOLT4
T-ALL cells. Consistent with the lack of ERG expression in mature T cells, there is no AcH3 enrichment at the ERG promoters and enhancer in CD4 and CD8 single positive T-cells ( Figure   S3 ).
13
To survey the chromatin accessibility profiles across the ERG loci in primary T-ALL cells, we performed ChIP-chip using H3K9/K14Ac ChIP material from a panel of NOD/SCID T-ALL xenografts hybridized to high-density Agilent custom arrays with oligomers tiled across the ERG locus to its flanking genes ( Figure 3C ). AcH3 enrichments are prominent at the ERG PP and +85 enhancer (marked with an arrow above the Vista sequence conservation plots) in all six T-ALL xenografts assayed by ChIP-chip. These enrichments were confirmed by quantitative PCR analysis of ChIP material. The promoter of ETS2, a related member of the Ets TF family that is immediately upstream of the ERG locus and known to be expressed in hematopoietic tissues, also has an active chromatin mark. Taken together, these results show that genomic sequences in the human ERG locus corresponding to the mouse Erg +85 enhancer are in an active configuration in CD34 + stem/progenitors, Pro-T and T-ALL cells.
The mErg +85 enhancer targets fetal and adult hematopoietic immature progenitors and shows selective activity in lineage committed cells.
T cell commitment in the human thymus parallels that in the mouse (reviewed in 29 ). To understand the activity of the Erg +85 enhancer during embryonic and adult hematopoiesis, we generated transgenic mouse lines expressing the Venus fluorescent reporter under control of the SV40 heterologous promoter and mErg +85 enhancer (SV/Venus/+85) (see schematic in Figure   4A ). Mice homozygous for a germline mutation in Erg (Erg
Mld2/Mld2
) that disrupts its transcriptional activity die in utero at E11.5-E13.5 with defects in definitive hematopoiesis 3 .
Erg
Mld2/+ mice survive to adulthood with cell intrinsic defects in HSC number and function. We have previously shown that the mErg +85 enhancer is active in fetal liver cells in transient Figure 4G ). Taken together, these data show that the Erg +85 HSC enhancer has stage specific activity which is restricted to immature thymic T-lymphocyte precursors.
The ERG +85 stem cell enhancer is active in T-ALL cells and relies on ETS/GATA/E-Box binding motifs
The ERG+85 region has blocks of sequences that are highly conserved from human to opossum including ETS (blue), GATA (red) and E-Box (yellow) consensus motifs ( Figure 5A ).
To test enhancer activity of this region in T-ALL cells, a 496bp fragment of PCR amplified human genomic sequence was sub-cloned into the pGL2P reporter vector and tested in stable To test the contribution of the conserved ETS/GATA and E-Box motifs to enhancer activity, a series of mutation constructs were generated and tested in stable transfection assays in MOLT4 cells ( Figure 5C ). The GATA binding motif at the 3' end of the enhancer (G2) does not contribute significantly to the activity of the enhancer. In contrast, the activity of the enhancer was abolished with the deletion of the 5' conserved E-Box and Ets (EB1-E1) motifs or a conserved block of sequences, which include a cluster of GATA, three conserved ETS, and two
flanking E-Box motifs (EB2-G1-E2/3/4-EB3). Within the EB2-G1-E2/3/4-EB3 block, loss of
the second E-Box motif (EB2) has a moderate effect whereas loss of both EB2 and the first Gata motif (G1) reduces activity to less than 50% implying that both these motifs contribute to the activity of the enhancer. The trio of Ets binding sites (E2/3/4) and the third E-Box motif (EB3) collectively and independently contribute to the activity of the enhancer, with the trio of Ets binding sites showing particular importance. Taken together, these data show that the activity of the ERG +85 enhancer in T-ALL cells is dependent on specific highly conserved Ets, Gata and E-box motifs.
The proto-oncogenes SCL, LYL1 and LMO2 as well as ETS and GATA factors bind the ERG +85 enhancer in T-ALL cells
Our understanding of the molecular basis of T-ALL is derived largely from analysis of recurrent chromosomal translocations and intrachromosomal rearrangements that juxtapose gene regulatory elements that drive expression of T cell receptor genes with a small set of TFs that are important during normal hematopoiesis, and include SCL/TAL1, LYL1 and LMO2 36 . Although the majority of T-ALLs aberrantly express one or more of these TFs only a minority have identifiable chromosomal abnormalities 37 . SCL and its paralogue, LYL1 are bHLH proteins that bind E-box motifs, whereas LMO2 is a transcriptional co-factor containing two LIM domain zinc-fingers that does not bind DNA directly but in a complex that may include either of the former and E2A, LDB1 and GATA factors 38 .
The transactivating factors that bind the ERG +85 enhancer and drive ERG expression in T-ALL cells, are not known. Given the activity of the ERG +85 enhancer during normal hematopoiesis and in T-ALL cells, as well as the contribution of the E-Box motifs to this activity, we assayed binding of SCL, LYL1 and LMO2 in 416B blood progenitors and Tleukaemic cells by RT-PCR ChIP assays ( Figure 5D ). We also assessed binding of FLI1 and ERG based on our previous observations in T-ALL cells 39 , and the enrichment of GATA factors, based on their known involvement in the composition of the SCL/LMO2 transcriptional complex 38 . A variable but definite in vivo enrichment of each of these TFs were identified at the ERG stem cell enhancer relative to IgG and a control region. Taken together, these data show that known T-ALL proto-oncogenes, SCL, LYL1 and LMO2 together with FLI1, ERG and GATA3, bind an accessible cis-regulatory element which drives ERG expression in leukaemic cells.
DISCUSSION
ERG is an Ets TF that is required for normal blood stem cell development 3 . It is overexpressed in T-ALL cells 39 and is recognized as an independent risk factor for an adverse outcome 11 . We report that transgenic mice over-expressing ERG in hematopoietic cells die with T-ALL and that ERG promotes the proliferation of human T-ALL cells. We show using locus-wide chromatin accessibility assays in primary human T-ALL xenografts, in vitro T-cell differentiation assays and transgenic reporter mice that ERG overexpression in T-ALL is likely to be caused by aberrant activation of the +85 enhancer. We show that this enhancer is transiently activated during normal T-cell ontogeny and in leukemic cells is bound by transcription factors that are typically activated in T-ALL. clusters of AcH3 enrichment are seen at the ERG PP and +85 element in 6/6 T-ALL xenografts.
Graphs at right show these peaks of enrichment confirmed by ChIP-PCR.
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